Christopher Alexander French
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Alexander French has a total of 442 co-authors. Here are the top co-authors by number of shared publications:
- Madeleine E. Lemieux
Bioinfo, Plantagenet, Canada
37 shared publications Prafulla C. Gokhale
Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA
33 shared publications- Ivona Filic
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
32 shared publications Philip A. Cole
32 shared publicationsTatiana M. Knox
32 shared publications- Geoffrey I. Shapiro
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
22 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Co-targeting CDK2 and CDK9 inhibits MYC oncogenic programs and has anti-tumor effects in CIC-rearranged sarcoma
Background: CIC -rearranged sarcoma is a rare and highly aggressive cancer that primarily affects children and young adults and has few effective treatment options. Previous studies have identified molecular dependence on cyclin-dependent kinase 2 (CDK2), but additional therapeutic vulnerabilities remain poorly defined. Here, we investigate the activity of CDK2-targeted therapies and evaluate combination strategies using new patient-derived models of CIC -rearranged sarcoma. Methods: We established patient-derived cell lines and matching xenograft models from tumors harboring CIC::DUX4 and CIC::NUTM1 fusions, with xenograft studies performed in 7-week-old female NSG mice. We assessed the effects of CDK2 inhibition alone and in combination with cyclin-dependent kinase 9 (CDK9) inhibition using molecular, functional, and transcriptomic analyses in vitro and in vivo. Results: Here we show that CIC -rearranged sarcoma depends on the MYC oncogene and is vulnerable to CDK2 inhibition. The CDK2 inhibitor tagtociclib suppresses MYC-regulated gene expression, inhibits tumor cell proliferation, and reduces tumor growth in patient-derived models. Combined inhibition of CDK2 and CDK9 produces synergistic anti-tumor activity by further suppressing MYC-driven transcription, enhancing apoptotic cell death, and improving tumor control in vitro and in vivo. Conclusions: These findings identify MYC-driven transcription as a therapeutic vulnerability in CIC -rearranged sarcoma and support combined CDK2 and CDK9 inhibition as a promising treatment strategy. The patient-derived models established in this study also provide valuable resources for future preclinical and translational research.
- 7 October 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessCo-targeting CDK2 and CDK9 inhibits MYC oncogenic programs and has anti-tumor effects in CIC-rearranged sarcoma
Background: CIC -rearranged sarcoma is a rare and highly aggressive cancer that primarily affects children and young adults and has few effective treatment options. Previous studies have identified molecular dependence on cyclin-dependent kinase 2 (CDK2), but additional therapeutic vulnerabilities remain poorly defined. Here, we investigate the activity of CDK2-targeted therapies and evaluate combination strategies using new patient-derived models of CIC -rearranged sarcoma. Methods: We established patient-derived cell lines and matching xenograft models from tumors harboring CIC::DUX4 and CIC::NUTM1 fusions, with xenograft studies performed in 7-week-old female NSG mice. We assessed the effects of CDK2 inhibition alone and in combination with cyclin-dependent kinase 9 (CDK9) inhibition using molecular, functional, and transcriptomic analyses in vitro and in vivo. Results: Here we show that CIC -rearranged sarcoma depends on the MYC oncogene and is vulnerable to CDK2 inhibition. The CDK2 inhibitor tagtociclib suppresses MYC-regulated gene expression, inhibits tumor cell proliferation, and reduces tumor growth in patient-derived models. Combined inhibition of CDK2 and CDK9 produces synergistic anti-tumor activity by further suppressing MYC-driven transcription, enhancing apoptotic cell death, and improving tumor control in vitro and in vivo. Conclusions: These findings identify MYC-driven transcription as a therapeutic vulnerability in CIC -rearranged sarcoma and support combined CDK2 and CDK9 inhibition as a promising treatment strategy. The patient-derived models established in this study also provide valuable resources for future preclinical and translational research.
- Open Access
BET bromodomain 2 inhibition facilitates SPOP-mediated degradation of chromatin-associated BRD4/BRD4-NUT, a therapeutic vulnerability in NUT carcinoma
BET bromodomain inhibitors block binding of BET family bromodomains 1 and 2 (BD1, BD2) to chromatin and have demonstrated clinical activity in NUT carcinoma (NC), a BRD-NUT fusion-driven cancer, but toxicity from BD1 inhibition has limited their effectiveness. We investigated whether selective inhibition of BRD4 bromodomain 2 (BD2) could retain antitumor activity while reducing toxicity. NC cells were uniquely sensitive to the novel BRD4-BD2 inhibitor DC-9476 and other BD2-selective inhibitors, which induced differentiation and growth arrest. A CRISPR knockout screen identified the BRD4-targeting E3 ligase SPOP as the top resistance hit. BD2 inhibition, but not BD1-selective or pan-BET inhibition, triggered SPOP-dependent proteasomal degradation of BRD4 and BRD4-NUT; SPOP loss prevented degradation and largely rescued BD2 inhibitor-induced differentiation and growth arrest. Unexpectedly, BRD4 and BRD4-NUT remained chromatin-associated during BD2 inhibition, whereas BD1 or pan-BET inhibition displaced them. Together with evidence that ectopic BRD4-NUT expression sensitizes BRD4 to degradation, these findings support a model in which BRD4-NUT megadomains create a high-density, degradation-competent SPOP substrate pool of BRD4 and BRD4-NUT upon BD2 inhibition, whereas pan-BET inhibition disperses this substrate and limits efficient degradation. In preclinical NC models, BD2-selective inhibition achieved greater tumor growth inhibition and survival benefit than pan-BET inhibition, revealing a therapeutic vulnerability.
Open AccessBET bromodomain 2 inhibition facilitates SPOP-mediated degradation of chromatin-associated BRD4/BRD4-NUT, a therapeutic vulnerability in NUT carcinoma
BET bromodomain inhibitors block binding of BET family bromodomains 1 and 2 (BD1, BD2) to chromatin and have demonstrated clinical activity in NUT carcinoma (NC), a BRD-NUT fusion-driven cancer, but toxicity from BD1 inhibition has limited their effectiveness. We investigated whether selective inhibition of BRD4 bromodomain 2 (BD2) could retain antitumor activity while reducing toxicity. NC cells were uniquely sensitive to the novel BRD4-BD2 inhibitor DC-9476 and other BD2-selective inhibitors, which induced differentiation and growth arrest. A CRISPR knockout screen identified the BRD4-targeting E3 ligase SPOP as the top resistance hit. BD2 inhibition, but not BD1-selective or pan-BET inhibition, triggered SPOP-dependent proteasomal degradation of BRD4 and BRD4-NUT; SPOP loss prevented degradation and largely rescued BD2 inhibitor-induced differentiation and growth arrest. Unexpectedly, BRD4 and BRD4-NUT remained chromatin-associated during BD2 inhibition, whereas BD1 or pan-BET inhibition displaced them. Together with evidence that ectopic BRD4-NUT expression sensitizes BRD4 to degradation, these findings support a model in which BRD4-NUT megadomains create a high-density, degradation-competent SPOP substrate pool of BRD4 and BRD4-NUT upon BD2 inhibition, whereas pan-BET inhibition disperses this substrate and limits efficient degradation. In preclinical NC models, BD2-selective inhibition achieved greater tumor growth inhibition and survival benefit than pan-BET inhibition, revealing a therapeutic vulnerability.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500526
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry
PURPOSE: Diagnostic delays are common for patients with NUT carcinoma (NC), a cancer driven by NUT fusion oncoprotein. Rapid diagnosis is crucial for the best outcomes. We investigated NC's presenting features and associations with diagnostic delays. METHODS: We manually reviewed medical records from US participants in the NC Registry (2007-2024). Baseline features were analyzed descriptively, and multivariable logistic regression was used to examine odds ratios for delays. RESULTS: We analyzed 132 patients (median age 37 years). At presentation, 55% had metastatic disease and 64% had a thoracic primary. The median interval from symptom onset to diagnosis was 10 weeks (range, 1-165 weeks). The initial histopathologic diagnosis was poorly differentiated/squamous cell cancer in 52%, insufficient malignant cells in 14%, carcinoma in 12%, and NC in 22%. Immunohistochemistry (IHC) testing revealed NUT in 100%; 93% were keratin+, 88% p63+, 89% p40+, and 72% had Ki-67 ≥50%. IHC was used to diagnose NC in 79%. Nonthoracic primaries were associated with a longer time between symptom onset and NC diagnosis (odds ratio, 3.25). Of 32 patients who started treatment before diagnosis, 78% were on agents appropriate for NC. After a diagnosis of NC, 33% participated in clinical trials. CONCLUSION: NC almost always presents as squamous/poorly differentiated non–small cell lung or head and neck cancer. Overall, 78% of patients were initially diagnosed as non-NC. Efforts to raise awareness, recognition, and rapid diagnosis of NC by both oncologists and pathologists are critical if we are to improve outcomes.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500526
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry
PURPOSE: Diagnostic delays are common for patients with NUT carcinoma (NC), a cancer driven by NUT fusion oncoprotein. Rapid diagnosis is crucial for the best outcomes. We investigated NC's presenting features and associations with diagnostic delays. METHODS: We manually reviewed medical records from US participants in the NC Registry (2007-2024). Baseline features were analyzed descriptively, and multivariable logistic regression was used to examine odds ratios for delays. RESULTS: We analyzed 132 patients (median age 37 years). At presentation, 55% had metastatic disease and 64% had a thoracic primary. The median interval from symptom onset to diagnosis was 10 weeks (range, 1-165 weeks). The initial histopathologic diagnosis was poorly differentiated/squamous cell cancer in 52%, insufficient malignant cells in 14%, carcinoma in 12%, and NC in 22%. Immunohistochemistry (IHC) testing revealed NUT in 100%; 93% were keratin+, 88% p63+, 89% p40+, and 72% had Ki-67 ≥50%. IHC was used to diagnose NC in 79%. Nonthoracic primaries were associated with a longer time between symptom onset and NC diagnosis (odds ratio, 3.25). Of 32 patients who started treatment before diagnosis, 78% were on agents appropriate for NC. After a diagnosis of NC, 33% participated in clinical trials. CONCLUSION: NC almost always presents as squamous/poorly differentiated non–small cell lung or head and neck cancer. Overall, 78% of patients were initially diagnosed as non-NC. Efforts to raise awareness, recognition, and rapid diagnosis of NC by both oncologists and pathologists are critical if we are to improve outcomes.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S2: Patients who had a NUT IHC test and underwent DNA, ctDNA, or RNA fusion testing specifically assaying for NUTM1 fusions.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S2: Patients who had a NUT IHC test and underwent DNA, ctDNA, or RNA fusion testing specifically assaying for NUTM1 fusions.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S3: Kaplan–Meier curve of overall survival from time of diagnostic testing. Survival curve showing overall survival from the date of the positive test that led to the diagnosis of NUT carcinoma. The y-axis indicates overall survival (%) and the x-axis represents time in months since testing.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S3: Kaplan–Meier curve of overall survival from time of diagnostic testing. Survival curve showing overall survival from the date of the positive test that led to the diagnosis of NUT carcinoma. The y-axis indicates overall survival (%) and the x-axis represents time in months since testing.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S4: Tumor mutation burden and PD-L1 expression among cases with DNA NGS testing. (A) Box-and-whisker plot showing tumor mutation burden (B) Bar chart showing the distribution of PD-L1 expression levels, stratified by tumor proportion score and combined proportion score. Expression levels are grouped into <1%, 1–49%, and ≥50%.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S4: Tumor mutation burden and PD-L1 expression among cases with DNA NGS testing. (A) Box-and-whisker plot showing tumor mutation burden (B) Bar chart showing the distribution of PD-L1 expression levels, stratified by tumor proportion score and combined proportion score. Expression levels are grouped into <1%, 1–49%, and ≥50%.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S2: Histopathological diagnosis in patients with NC who only had a NUT IHC test. Donut chart displaying the distribution of diagnoses among patients diagnosed with NUT carcinoma based only on IHC. Diagnostic categories include “carcinoma”, and a single case categorized as “other” due to limited tissue.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S2: Histopathological diagnosis in patients with NC who only had a NUT IHC test. Donut chart displaying the distribution of diagnoses among patients diagnosed with NUT carcinoma based only on IHC. Diagnostic categories include “carcinoma”, and a single case categorized as “other” due to limited tissue.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S3: Co-occurring mutations found in DNA-based NGS with clinical relevance in NUT carcinoma.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S3: Co-occurring mutations found in DNA-based NGS with clinical relevance in NUT carcinoma.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S6: Schematic of an example gene fusion event leading to NUT carcinoma pathogenesis. Diagram illustrating the fusion of the BRD4 and NUTM1 genes following chromosomal rearrangement. The NUTM1 fusion protein drives oncogenic transcription through upregulation of target genes such as MYC, SOX2, and p63.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S6: Schematic of an example gene fusion event leading to NUT carcinoma pathogenesis. Diagram illustrating the fusion of the BRD4 and NUTM1 genes following chromosomal rearrangement. The NUTM1 fusion protein drives oncogenic transcription through upregulation of target genes such as MYC, SOX2, and p63.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S1: Flowchart of patient selection and cohort assignment. Flow diagram illustrating the inclusion and exclusion of patients from the NUT carcinoma registry. Boxes show the number of patients included/excluded and how patients were assigned to the various cohorts.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S1: Flowchart of patient selection and cohort assignment. Flow diagram illustrating the inclusion and exclusion of patients from the NUT carcinoma registry. Boxes show the number of patients included/excluded and how patients were assigned to the various cohorts.